Aclaris Therapeutics Inc. (ACRS) Receives New Coverage from Analysts at Leerink Swann
Equities research analysts at Leerink Swann started coverage on shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) in a research report issued to clients and investors on Tuesday. The firm set an “outperform” rating on the stock.
Other equities analysts also recently issued research reports about the company. Jefferies Group reissued a “buy” rating and set a $32.00 target price (up previously from $29.00) on shares of Aclaris Therapeutics in a research report on Friday, November 18th. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Finally, JMP Securities initiated coverage on Aclaris Therapeutics in a research report on Friday, September 30th. They set an “outperform” rating and a $34.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Aclaris Therapeutics currently has a consensus rating of “Buy” and an average target price of $32.50.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded down 1.2741% during trading on Tuesday, hitting $29.5684. The stock had a trading volume of 223,944 shares. The company’s market cap is $633.71 million. Aclaris Therapeutics has a 12 month low of $14.12 and a 12 month high of $33.88. The stock has a 50-day moving average price of $23.20 and a 200 day moving average price of $21.47.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, November 3rd. The company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.16. Equities analysts expect that Aclaris Therapeutics will post ($2.38) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Aclaris Therapeutics Inc. (ACRS) Receives New Coverage from Analysts at Leerink Swann” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/29/aclaris-therapeutics-inc-acrs-coverage-initiated-at-leerink-swann.html.
In other Aclaris Therapeutics news, insider Kamil Ali-Jackson sold 1,841 shares of the company’s stock in a transaction on Wednesday, September 28th. The stock was sold at an average price of $24.66, for a total value of $45,399.06. Following the transaction, the insider now owns 77,798 shares of the company’s stock, valued at approximately $1,918,498.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 907,828 shares of the company’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $23.03, for a total value of $20,907,278.84. The disclosure for this sale can be found here. 46.40% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. FIL Ltd acquired a new position in shares of Aclaris Therapeutics during the second quarter valued at approximately $13,801,000. Vanguard Group Inc. increased its position in shares of Aclaris Therapeutics by 147.6% in the second quarter. Vanguard Group Inc. now owns 419,184 shares of the company’s stock valued at $7,743,000 after buying an additional 249,888 shares during the period. BlackRock Fund Advisors increased its position in shares of Aclaris Therapeutics by 59.7% in the second quarter. BlackRock Fund Advisors now owns 234,696 shares of the company’s stock valued at $4,335,000 after buying an additional 87,739 shares during the period. Monashee Investment Management LLC acquired a new position in shares of Aclaris Therapeutics during the second quarter valued at approximately $1,108,000. Finally, HighTower Advisors LLC acquired a new position in shares of Aclaris Therapeutics during the second quarter valued at approximately $959,000. 72.10% of the stock is currently owned by institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor.
Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.